Form 4 for ALDX Aldeyra Therapeutics, Inc.

Accepted 2022-07-19 00:00:00 ET · period of report 2022-07-15 · accession 0000899243-22-026344 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-07-19	2022-07-15	ALDX	Machatha Stephen	Chief Development Off	A - Grant	$0.00	+185.6K	273.3K	+212%	$0
D	2022-07-19	2022-07-15	ALDX	Machatha Stephen	Chief Development Off	A - Grant	$0.00	+69.5K	69.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-07-15	A	A	185,605	$0.00	273,263	D	—	—	(F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
2	Derivative	Bonus Units	2022-07-15	A	A	69,473	$0.00	69,473	D	— · — to —	69,473 Common Stock	(F3) Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.